China-based Beijing Luzhu Biotechnology Co., Ltd has reportedly secured an undisclosed amount in a Series C (crossover) financing round led by Huapu Haihe Biomedical Fund, Yizhuang Biomedical Fund, and CNCB (Beijing) Equity Investment Fund. This latest funding follows previous rounds including RMB 350 million (USD 52.3 million) in Series B and RMB 120 million (USD 17.9 million) in Series B+ financing rounds held in August 2021 and January 2022, respectively.
Company Background and Product Portfolio
Founded in 2001, Luzhu Bio is recognized for its bacterial polysaccharide protein conjugate vaccines and high-purity, low-pyrogen polysaccharide vaccines, which are licensed to Zhifei Bio (SHE: 300122). The company made history as the first globally to develop Group A and C meningococcal polysaccharide conjugate vaccines.
Pipeline and Innovation
Luzhu Bio’s pipeline is rich with monoclonal antibodies and bispecific antibodies (BsAbs) targeting autoimmune diseases. Notably, the company’s shingles vaccine LZ901 is currently in Phase II clinical trials. This robust pipeline underscores Luzhu Bio’s commitment to innovation and its potential to impact the global vaccine market.-Fineline Info & Tech
